Stock Scorecard
Stock Summary for Werewolf Therapeutics Inc (HOWL) - $1.37 as of 9/4/2025 1:37:05 PM EST
Total Score
7 out of 30
Safety Score
22 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for HOWL
Positive Quarterly and Annual earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the Annual earnings growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for HOWL
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for HOWL
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for HOWL
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for HOWL (22 out of 100)
Stock Price Rating (Max of 10) | 2 |
Historical Stock Price Rating (Max of 10) | 5 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 1 |
Analyst Buy Ratings (Max of 5) | 4 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 4 |
Price to Earnings (Max of 10) | 0 |
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for HOWL
Financial Details for HOWL
Company Overview |
|
---|---|
Ticker | HOWL |
Company Name | Werewolf Therapeutics Inc |
Country | USA |
Description | Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | HEALTHCARE |
Industry Name | BIOTECHNOLOGY |
Most Recent Quarter | 6/30/2025 |
Next Earnings Date | 11/6/2025 |
Stock Price History |
|
Last Day Price | 1.37 |
Price 4 Years Ago | 11.91 |
Last Day Price Updated | 9/4/2025 1:37:05 PM EST |
Last Day Volume | 123,054 |
Average Daily Volume | 161,139 |
52-Week High | 4.18 |
52-Week Low | 0.59 |
Last Price to 52 Week Low | 132.20% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 27.24 |
Sector PE | 40.17 |
5-Year Average PE | -1.44 |
Free Cash Flow Ratio | 0.80 |
Industry Free Cash Flow Ratio | 11.70 |
Sector Free Cash Flow Ratio | 28.68 |
Current Ratio Most Recent Quarter | 5.30 |
Total Cash Per Share | 1.72 |
Book Value Per Share Most Recent Quarter | 0.92 |
Price to Book Ratio | 1.43 |
Industry Price to Book Ratio | 43.13 |
Sector Price to Book Ratio | 45.62 |
Price to Sales Ratio Twelve Trailing Months | 52.22 |
Industry Price to Sales Ratio Twelve Trailing Months | 30.35 |
Sector Price to Sales Ratio Twelve Trailing Months | 11.64 |
Analyst Buy Ratings | 4 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 45,729,000 |
Market Capitalization | 62,648,730 |
Institutional Ownership | 49.19% |
Dividends |
|
Ex-Dividend Date | N/A |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.0000 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -88.70% |
Reported EPS 12 Trailing Months | -1.64 |
Reported EPS Past Year | -0.80 |
Reported EPS Prior Year | -1.66 |
Net Income Twelve Trailing Months | -73,144,000 |
Net Income Past Year | -70,515,000 |
Net Income Prior Year | -37,368,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | 0.00% |
Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 78,491,000 |
Total Cash Past Year | 110,995,000 |
Total Cash Prior Year | 134,343,000 |
Net Cash Position Most Recent Quarter | 53,786,000 |
Net Cash Position Past Year | 84,900,000 |
Long Term Debt Past Year | 26,095,000 |
Long Term Debt Prior Year | 32,656,000 |
Total Debt Most Recent Quarter | 24,705,000 |
Equity to Debt Ratio Past Year | 0.74 |
Equity to Debt Ratio Most Recent Quarter | 0.63 |
Total Stockholder Equity Past Year | 73,390,000 |
Total Stockholder Equity Prior Year | 111,374,000 |
Total Stockholder Equity Most Recent Quarter | 41,464,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -60,952,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.33 |
Free Cash Flow Past Year | -56,442,000 |
Free Cash Flow Prior Year | -33,381,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.03 |
MACD Signal | 0.02 |
20-Day Bollinger Lower Band | 0.81 |
20-Day Bollinger Middle Band | 1.16 |
20-Day Bollinger Upper Band | 1.51 |
Beta | 0.64 |
RSI | 60.60 |
50-Day SMA | 1.49 |
150-Day SMA | 2.74 |
200-Day SMA | 3.89 |
System |
|
Modified | 9/4/2025 1:31:04 AM EST |